RxDoctor Payments Data

Mary Dickerson

Family · Frankford, DENPI 1689005225

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 49 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$205
  • Exact Sciences$169
  • AstraZeneca$165
  • Merz North America, Inc.$112
  • Lilly USA, LLC$69
  • Pfizer$54
  • plus $242 from 8 others

What the payments were for

  • Food & beverage$99298%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 65th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$35,046
Medicare patients
153
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$24,086
XareltoRivaroxaban23$23,605
MounjaroTirzepatide20$20,724
JanumetSitagliptin Phos/Metformin Hcl12$6,919
JanuviaSitagliptin Phosphate11$6,745
Duloxetine Hcl20$1,741
Albuterol Sulfate HfaAlbuterol Sulfate45$1,590
Bupropion XlBupropion Hcl30$1,457
Rosuvastatin Calcium59$1,034
Atorvastatin Calcium123$1,025
Esomeprazole Magnesium11$989
Gabapentin69$925
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide16$885
SynthroidLevothyroxine Sodium15$751
Omeprazole65$747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$24,08623 claims
Lilly USA, LLCMounjaro$69$20,72420 claims
MerckJanumet, Januvia$34$13,66523 claims
AbbVieSynthroid$15$75115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 523 family providers in Delaware.

Other family in Frankford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →